Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
BMC Musculoskelet Disord ; 24(1): 246, 2023 Mar 30.
Artículo en Inglés | MEDLINE | ID: mdl-36997896

RESUMEN

BACKGROUND: Immune and non-immune cells contribute to the pathology of chronic arthritis, and they can contribute to tissue remodeling and repair as well as disease pathogenesis. The present research aimed to analyze inflammation and bone destruction/regeneration biomarkers in patients with psoriatic arthritis (PsA), rheumatoid arthritis (RA), osteoarthritis (OA), and ankylosing spondylitis (AS). METHODS: Samples were obtained from the inflamed knee of patients with knee arthritis who had been referred for undergoing arthroscopies. The synovial membrane was processed for pathological description, IHC analysis, and quantification of mRNA expression ratio by qRT-PCR. Serum levels of TGF-ß1, IL-23, IL-6, IL-17 A, IL-22, Dkk1, Sclerostin, BMP2, BMP4, Wnt1, and Wnt5a were measured by ELISA. All these data were analyzed and compared with the demographic, clinical, blood tests, and radiological characteristics of the patients. RESULTS: The synovial membrane samples were obtained from 42 patients for IHC, extraction, and purification of RNA for synovial mRNA expression analysis, and serum for measuring protein levels from 38 patients. IHC reactivity for TGF-ß1 in the synovial tissue was higher in patients with psoriatic arthritis (p 0.036) and was positively correlated with IL-17 A (r = 0.389, p = 0.012), and Dkk1 (r = 0.388, p = 0.012). Gene expression of the IL-17 A was higher in PsA patients (p = 0.018) and was positively correlated with Dkk1 (r = 0.424, p = 0.022) and negatively correlated with BMP2 (r = -0.396, p = 0.033) and BMP4 (r = -0.472, p = 0.010). It was observed that IHC reactivity for TGF-ß1 was higher in patients with erosive PsA (p = 0.024). CONCLUSIONS: The IHC reactivity of TGF-ß1 in synovial tissue was higher in patients with erosive psoriatic arthritis, and TGF-ß1 was in relation to higher levels of gene expression of IL-17 A and Dkk1.


Asunto(s)
Artritis Psoriásica , Humanos , Factor de Crecimiento Transformador beta1/metabolismo , Interleucina-17/metabolismo , Líquido Sinovial/metabolismo , Inmunohistoquímica , Membrana Sinovial/patología , ARN Mensajero/metabolismo
2.
Eur Cell Mater ; 36: 96-109, 2018 09 11.
Artículo en Inglés | MEDLINE | ID: mdl-30204229

RESUMEN

The establishment of cartilage regenerative medicine is an important clinical issue, but the search for cell sources able to restore cartilage integrity proves to be challenging. Human mesenchymal stromal cells (MSCs) are prone to form epiphyseal or hypertrophic cartilage and have an age-related limited proliferation. On the other hand, it is difficult to obtain functional chondrocytes from human embryonic stem cells (ESCs). Moreover, the ethical issues associated with human ESCs are an additional disadvantage of using such cells. Since their discovery in 2006, induced pluripotent stems cells (iPSCs) have opened many gateways to regenerative medicine research, especially in cartilage tissue engineering therapies. iPSCs have the capacity to overcome limitations associated with current cell sources since large numbers of autologous cells can be derived from small starting populations. Moreover, problems associated with epiphyseal or hypertrophic-cartilage formation can be overcome using iPSCs. iPSCs emerge as a promising cell source for treating cartilage defects and have the potential to be used in the clinical field. For this purpose, robust protocols to induce chondrogenesis, both in vitro an in vivo, are required. This review summarises the recent progress in iPSC technology and its applications for cartilage repair.


Asunto(s)
Cartílago/patología , Células Madre Pluripotentes Inducidas/citología , Cicatrización de Heridas , Animales , Diferenciación Celular , Condrogénesis , Cuerpos Embrioides/citología , Humanos , Trasplante de Células Madre
3.
Respiration ; 62(1): 53-6, 1995.
Artículo en Inglés | MEDLINE | ID: mdl-7716358

RESUMEN

We describe a 41-year-old patient with adult-onset dermatomyositis who developed persistent pneumomediastinum and severe subcutaneous emphysema due to end-stage interstitial lung disease. The diagnosis of dermatomyositis was based on proximal muscle weakness, electromyographic findings of inflammatory myopathy, and positive findings on muscle biopsy. Low levels of creatine kinase elevation were found at the time of diagnosis (a form of dermatomyositis which has been associated with a poor prognosis). The patient had no signs of cutaneous vasculitis. Despite treatment with prednisone and azathioprine, she died of intercurrent gram-negative sepsis 15 months after the diagnosis of dermatomyositis.


Asunto(s)
Dermatomiositis/complicaciones , Enfermedades Pulmonares Intersticiales/complicaciones , Enfisema Mediastínico/etiología , Enfisema Subcutáneo/etiología , Adulto , Edad de Inicio , Biopsia con Aguja , Broncoscopía , Enfermedad Crónica , Dermatomiositis/diagnóstico , Dermatomiositis/tratamiento farmacológico , Resultado Fatal , Femenino , Humanos , Enfermedades Pulmonares Intersticiales/diagnóstico , Enfermedades Pulmonares Intersticiales/terapia , Enfisema Mediastínico/diagnóstico , Enfisema Mediastínico/terapia , Prednisona/uso terapéutico , Enfisema Subcutáneo/diagnóstico , Enfisema Subcutáneo/terapia , Toracotomía
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA